• Explore /
  • Poster
  • / Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

Abstract Poster

Authors

null

Scott N. Gettinger

Yale School of Medicine and Smilow Cancer Center, Yale New Haven Hospital, New Haven, CT

Scott N. Gettinger , Rudolf M. Huber , Dong-Wan Kim , Lyudmila Bazhenova , Karin Holmskov Hansen , Marcello Tiseo , Corey J. Langer , Luis G. Paz-Ares , Howard West , Karen L. Reckamp , Glen J. Weiss , Egbert F. Smit , Maximilian Hochmair , Sang-We Kim , Myung-Ju Ahn , Edward S. Kim , Harry J.M. Groen , Joanna Pye , Florin Vranceanu , D. Ross Camidge

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01449461, NCT02094573

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 9071)

DOI

10.1200/JCO.2021.39.15_suppl.9071

Abstract #

9071

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Brigatinib in Japanese patients (pts) with <em>ALK</em>+ NSCLC: Final results from the phase 2 J-ALTA trial.

Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.

First Author: Pingkuan Zhang

First Author: Michaël Duruisseaux

First Author: Haruko Daga

First Author: Edward S. Kim